Amneal Pharmaceuticals Inc. has announced that it received approval from the U.S. Food and Drug Administration (FDA) for its prednisolone acetate ophthalmic suspension, 1% sterile, which is a reference to Pred Forte®. This product, designed to treat steroid-responsive ocular inflammation, is part of Amneal's Affordable Medicines segment. The commercial launch is scheduled for the third quarter of 2025. Andy Boyer, Executive Vice President and Chief Commercial Officer of Affordable Medicines, highlighted the approval as a testament to Amneal's R&D capabilities and manufacturing strength. The U.S. market for this product is significant, with annual sales reaching approximately $201 million as of April 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.